Coinbase Co-Founder’s Longevity Startup NewLimit Raises $435M for Human Trials

Published by

Nidhi Kolhapur

June 3, 2026

London Stock Exchange Launches Blockchain Platform for Private Funds

NewLimit, a longevity biotechnology company co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in a Series C funding round led by Founders Fund. New investors, including Thrive Capital, Greenoaks and Quiet Capital, joined existing backers such as Kleiner Perkins and Eli Lilly Ventures. The company develops age-reprogramming therapies designed to restore cell function affected by aging. The funding will support research and development as NewLimit prepares to move its first drug candidate into human clinical trials next year. The milestone marks a significant step toward testing its technology in patients.

Trust with CoinPedia:

CoinPedia has been delivering accurate and timely cryptocurrency and blockchain updates since 2017. All content is created by our expert panel of analysts and journalists, following strict Editorial Guidelines based on E-E-A-T (Experience, Expertise, Authoritativeness, Trustworthiness). Every article is fact-checked against reputable sources to ensure accuracy, transparency, and reliability. Our review policy guarantees unbiased evaluations when recommending exchanges, platforms, or tools. We strive to provide timely updates about everything crypto & blockchain, right from startups to industry majors.

Investment Disclaimer:

All opinions and insights shared represent the author's own views on current market conditions. Please do your own research before making investment decisions. Neither the writer nor the publication assumes responsibility for your financial choices.